When the Microbiome Meets Cancer Immunotherapy – LWW Journals
|
When the Microbiome Meets Cancer Immunotherapy
LWW Journals Recent preclinical studies in animals have shown that anticancer immunotherapy by the anti-PD-L1 checkpoint inhibitor CTLA-4 relies on the presence of certain gut microbiota (Science 2015;350(6264):1079-1084, Science 2015;350(6264):1084-1089). |
